Top

Published in:

01-12-2012

Plasticity of disseminating cancer cells in patients with epithelial malignancies

Authors: Natalia Bednarz-Knoll, Catherine Alix-Panabières, Klaus Pantel

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Abstract

Current models suggest that at a certain but yet undefined time point of tumour development malignant cells with an aggressive phenotype start to disseminate via the blood stream into distant organs. This invasive phenotype appears to be associated with an epithelial–mesenchymal transition (EMT), which enables detachment of tumour cells from a primary site and migration. The reverse process of mesenchymal–epithelial transition (MET) might play a crucial role in the further steps of metastasis when circulating tumour cells (CTCs) settle down in distant organs and establish (micro-)metastasis. Nevertheless, the exact mechanisms and interplay of EMT and MET are only partially understood and their relevance in cancer patients is unclear. Research groups have just started to apply EMT-related markers in their studies on CTCs in cancer patients. In the present review, we summarize and discuss the current state of investigations on CTCs in the context of research on EMT/MET.

Pantel, K., & Brakenhoff, R. H. (2004). Dissecting the metastatic cascade. Nature Reviews Cancer, 4(6), 448–456.PubMed

Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008). Detection, clinical relevance and specific biological properties of disseminating tumor cells. Nature Reviews Cancer, 8(5), 329–340.PubMed

Pantel, K., Alix-Panabières, C., & Riethdorf, S. (2009). Cancer micrometastases. Nature Reviews Clinical Oncology, 6(6), 339–351.PubMed

Bednarz-Knoll, N., Alix-Panabières, C., & Pantel, K. (2011). Clinical relevance and biology of circulating tumor cells. Breast Cancer Research, 3(6), 228.

Alix-Panabières, C., Schwarzenbach, H., & Pantel, K. (2012). Circulating tumor cells and circulating tumor DNA. Annual Review of Medicine, 63, 199–215.PubMed

Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E., Miller, M. C., Matera, J., Repollet, M., Doyle, G. V., Terstappen, L. W., & Hayes, D. F. (2006). Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clinical Cancer Research, 12(21), 6403–6409.PubMed

Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W., & Meropol, N. J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(19), 3213–3221.PubMed

de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W., Pienta, K. J., & Raghavan, D. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302–6309.PubMed

Thompson, E. W., & Williams, E. D. (2008). EMT and MET in carcinoma-clinical observations, regulatory pathways and new models. Clinical and Experimental Metastasis, 25(6), 591–592.PubMed

10.

Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.PubMed

11.

Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial–mesenchymal transitions in development and disease. Cell, 139(5), 871–890.PubMed

12.

Thiery, J. P., & Sleeman, J. P. (2006). Complex networks orchestrate epithelial–mesenchymal transitions. Nature Reviews Molecular Cell Biology, 7(2), 131–142.PubMed

13.

Zeisberg, M., & Neilson, E. G. (2009). Biomarkers for epithelial–mesenchymal transitions. Journal of Clinical Investigation, 119(6), 1429–1437.PubMed

14.

Sleeman, J. P., & Thiery, J. P. (2011). SnapShot: the epithelial–mesenchymal transition. Cell, 145(1), 162.e1.PubMed

15.

Kalluri, R., & Weinberg, R. A. (2009). The basics of epithelial–mesenchymal transition. Journal of Clinical Investigation, 119(6), 1420–1428.PubMed

16.

Bonnomet, A., Brysse, A., Tachsidis, A., Waltham, M., Thompson, E. W., Polette, M., & Gilles, C. (2010). Epithelial-to-mesenchymal transitions and circulating tumor cells. Journal of Mammary Gland Biology and Neoplasia, 15(2), 261–273.PubMed

17.

Thompson, E. W., & Haviv, I. (2011). The social aspects of EMT-MET plasticity. Nature Medicine, 17(9), 1101–1109.

18.

Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572.PubMed

19.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMed

20.

Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9(4), 302–312.PubMed

21.

Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., Leach, S. D., & Stanger, B. Z. (2012). EMT and dissemination precede pancreatic tumor formation. Cell, 148(1–2), 349–361.PubMed

22.

Hüsemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., Forni, G., Eils, R., Fehm, T., Riethmüller, G., & Klein, C. A. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58–68.PubMed

23.

Sänger, N., Effenberger, K. E., Riethdorf, S., Van Haasteren, V., Gauwerky, J., Wiegratz, I., Strebhardt, K., Kaufmann, M., & Pantel, K. (2011). Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. International Journal of Cancer, 129(10), 2522–2526.

24.

Pantel, K., Denève, E., Nocca, D., Coffy, A., Vendrell, J. P., Maudelonde, T., Riethdorf, S., & Alix-Panabières, C. (2012). Circulating epithelial cells in patients with benign colon diseases. Clinical Chemistry, 58, 936–940.PubMed

25.

Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252.PubMed

26.

Schmidt, H., De Angelis, G., Eltze, E., Gockel, I., Semjonow, A., & Brandt, B. (2006). Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harbouring loss of heterozygosity of the PTEN gene. Cancer Research, 66(18), 8959–8965.PubMed

27.

Swennenhuis, J. F., Tibbe, A. G. J., Levink, R., Sipkema, R. C. J., & Terstappen, L. W. (2009). Characterization of circulating tumour cells by fluorescence in situ hybridization. Cytometry A, 75(6), 520–527.PubMed

28.

Hou, J. M., Krebs, M., Ward, T., Sloane, R., Priest, L., Hughes, A., Clack, G., Ranson, M., Blackhall, F., & Dive, C. (2011). Circulating tumor cells as a window on metastasis biology in lung cancer. The American Journal of Pathology, 178(3), 989–996.PubMed

29.

Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., et al. (2011). A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 106(3), 508–516.PubMed

30.

Schmidt, H., De Angelis, G., Bettendorf, O., Eltze, E., Semjonow, A., Knichwitz, G., & Brandt, B. (2004). Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients. International Journal of Biological Markers, 19(2), 93–99.PubMed

31.

Crane, K. (2011). Elucidating an uncommon disease: inflammatory breast cancer. Journal of National Cancer Institute, 103(18), 1358–1360.

32.

Krebs, M. G., Hou, J.-M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., Ward, T. H., et al. (2011). Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. Journal of Thoracic Oncology, 7(2), 306–315.

33.

Lianidou, E.S., Markou, A., Strati, A. (2012). Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer & Metastasis Reviews (in press)

34.

Kallergi, G., Agelaki, S., Kalykaki, A., Stournaras, C., Mavroudis, D., & Georgoulias, V. (2008). Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Research, 10(5), R80.PubMed

35.

Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T., Schrader, I., Hilfrich, J., Holms, F., Tesch, H., Eidtmann, H., Untch, M., von Minckwitz, G., & Pantel, K. (2010). Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research, 16(9), 2634–2645.PubMed

36.

Aktas, B., Müller, V., Tewes, M., Zeitz, J., Kasimir-Bauer, S., Loehberg, C. R., Rack, B., Schneeweiss, A., & Fehm, T. (2011). Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol, 122(2), 356–360.PubMed

37.

Banys, M., Krawczyk, N., Becker, S., Jakubowska, J., Staebler, A., Wallwiener, D., Fehm, T., & Rothmund, R. (2012). The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Research & Treatment, 131(2), 501–508.

38.

Gradilone, A., Naso, G., Raimondi, C., Cortesi, E., Gandini, O., Vincenti, B., Saltarelli, R., Chiapparono, E., Spremberg, F., Cristofanilli, M., Frati, L., Agliano, A. M., & Gazzaniga, P. (2011). Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology, 22(1), 86–92.PubMed

39.

Larson, C. J., Moreno, J. G., Pienta, K. J., Gross, S., Repollet, M., O’Hara, S. M., Russell, T., & Terstappen, L. W. M. M. (2004). Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A, 62A, 46–53.

40.

Rossi, E., Basso, U., Celadin, R., Zilio, F., Pucciarelli, S., Aieta, M., Barile, C., Sava, T., Bonciarelli, G., Tumolo, S., Ghiotto, C., Magro, C., Jirillo, A., Indraccolo, S., Amadori, A., & Zamarchi, R. (2010). M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by cell search analysis. Clinical Cancer Research, 16(21), 5233–5243.PubMed

41.

Müller, V., Stahmann, N., Riethdorf, S., Rau, T., Zabel, T., Goetz, A., Jänicke, F., & Pantel, K. (2005). Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research, 11(10), 678–3685.

42.

Stott, S. L., Lee, R. J., Nagrath, S., Yu, M., Miyamoto, D. T., Ulkus, L., et al. (2010). Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Science Translational Medicine, 2(25), 25ra23.PubMed

43.

Wyckoff, J. B., Jones, J. G., Condeelis, J. S., & Segall, J. E. (2000). A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Research, 60(9), 2504–2511.PubMed

44.

Goss, P. E., & Chambers, A. F. (2010). Does tumour dormancy offer a therapeutic target? Nature Reviews Cancer, 10(12), 871–877.PubMed

45.

Uhr, J. W., & Pantel, K. (2011). Controversies in clinical cancer dormancy. Proceedings of the National Academy of Sciences, 108(30), 12396–12400.

46.

Psaila, B., & Lyden, D. (2009). The metastatic niche: adapting the foreign soil. Nature Reviews Cancer, 9(4), 285–293.PubMed

47.

Sleeman, J. P. (2012). The metastatic niche and stromal progression. Cancer & Metastasis Reviews. doi:10.1007/s10555-012-9373-9.

48.

Nguyen, D. X., Bos, P. D., & Massagué, J. (2009). Metastasis: from dissemination to organ-specific colonization. Nature Reviews Cancer, 9(4), 274–284.PubMed

49.

Navin, N. E., & Hicks, J. (2010). Tracing the tumor lineage. Molecular Oncology, 4(3), 267–283.PubMed

50.

Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., & Massagué, J. (2009). Tumor self-seeding by circulating cancer cells. Cell, 139(7), 1315–1326.PubMed

51.

Comen, E., Norton, L., & Massagué, J. (2011). Clinical implications of cancer self-seeding. Nature Reviews Clinical Oncology, 8(6), 369–377.PubMed

52.

Bidard, F. C., Vincent-Salomon, A., Gomme, S., Nos, C., de Rycke, Y., Thiery, J. P., Sigal-Zafrani, B., Mignot, L., Sastre-Garau, X., Pierga, J. Y., & Institut Curie Breast Cancer Study Group. (2008). Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clinical Cancer Research, 14(11), 3306–3311.PubMed

53.

Bidard, F. C., Kirova, Y. M., Vincent-Salomon, A., Alran, S., de Rycke, Y., Sigal-Zafrani, B., Sastre-Garau, X., Mignot, L., Fourquet, A., & Pierga, J. Y. (2009). Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Annals of Oncologyl, 20(11), 1836–1841.

54.

Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., Fritsche, H. A., Hortobagyi, G. N., & Terstappen, L. W. (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology, 23(7), 1420–1430.PubMed

55.

Stoecklein, N. H., & Klein, C. A. (2010). Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer, 126(3), 589–598.

56.

Hannemann, J., Meyer-Staeckling, S., Kemming, D., Alpers, I., Joosse, S. A., Pospisil, H., Kurtz, S., Görndt, J., Püschel, K., Riethdorf, S., Pantel, K., & Brandt, B. (2011). Quantitative high-resolution genomic analysis of single cancer cells. Public Library of Science One, 6(11), e26362.PubMed

57.

Vona, G., Sabile, A., Louha, M., Sitruk, V., Romana, S., Schütze, K., Capron, F., Franco, D., Pazzagli, M., Vekemans, M., Lacour, B., Bréchot, C., & Paterlini-Bréchot, P. (2000). Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Americal Journal of Pathology, 156, 57–63.

58.

Pinzani, P., Salvadori, B., Simi, L., Bianchi, S., Distante, V., Cataliotti, L., Pazzagli, M., & Orlando, C. (2006). Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Human Pathology, 37, 711–718.PubMed

59.

Zheng, S., Lin, H. K., Lu, B., Williams, A., Datar, R., Cote, R. J., & Tai, Y. C. (2011). 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices, 13(1), 203–213.PubMed

60.

Tan, S. J., Lakshmi, R. L., Chen, P., Lim, W. T., Yobas, L., & Lim, C. T. (2010). Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron, 26, 1701–1705.PubMed

61.

Moon, H. S., Kwon, K., Kim, S. I., Han, H., Sohn, J., Lee, S., & Jung, H. I. (2011). Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip, 11(6), 1118–1125.PubMed

62.

Gascoyne, P. R., Noshari, J., Anderson, T. J., & Becker, F. F. (2009). Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis, 30, 1388–1398.PubMed

63.

Bednarz, N., Eltze, E., Semjonow, A., Rink, M., Andreas, A., Mulder, L., Hannemann, J., Fisch, M., Pantel, K., Weier, U.-H. G., Bielawski, K. P., & Brandt, B. (2010). BRCA1 loss pre-existing in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clinical Cancer Research, 16(13), 3340–3348.PubMed

64.

Fehm, T., Müller, V., Alix-Panabières, C., & Pantel, K. (2008). Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Research, 10(Suppl 1), S1.PubMed

65.

Königsberg, R., Obermayr, E., Bises, G., Pfeiler, G., Gneist, M., Wrba, F., De Santis, M., Zeillinger, R., Hudec, M., & Dittrich, C. (2011). Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncologica, 50(5), 700–710.PubMed

66.

Mostert, B., Kraan, J., Bolt-de Vries, J., van der Spoel, P., Sieuwerts, A. M., Schutte, M., Timmermans, A. M., Foekens, R., Martens, J. W., Gratama, J. W., Foekens, J. A., & Sleijfer, S. (2011). Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Research & Treatment, 127(1), 33–41.

67.

Marth, C., Kisic, J., Kaern, J., Tropé, C., & Fodstad, Ø. (2002). Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer, 94(3), 707–712.PubMed

68.

Sieuwerts, A. M., Kraan, J., Bolt, J., van der Spoel, P., Elstrodt, F., Schutte, M., Martens, J. W., Gratama, J. W., Sleijfer, S., & Foekens, J. A. (2009). Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Instutute, 101(1), 61–66.

69.

Aktas, B., Kasimir-Bauer, S., Heubner, M., Kimmig, R., & Wimberger, P. (2011). Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. International Journal of Gynecological Cancer, 21(5), 822–830.PubMed

70.

de Albuquerque, A., Kubisch, I., Breier, G., Stamminger, G., Fersis, N., Eichler, A., Kaul, S., & Stölzel, U. (2012). Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology, 82(1), 3–10.PubMed

71.

Joosse, S. A., Hannemann, J., Spötter, J., Bauche, A., Andreas, A., Müller, V., & Pantel, K. (2012). Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clinical Cancer Research, 18(4), 993–1003.PubMed

72.

Effenberger, K. E., Borgen, E., Eulenburg, C. Z., Bartkowiak, K., Grosser, A., Synnestvedt, M., Kaaresen, R., Brandt, B., Nesland, J. M., Pantel, K., & Naume, B. (2011). Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Research and Treatment, 125(3), 729–738.PubMed

73.

Christiansen, J. J., & Rajasekaran, A. K. (2006). Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Research, 66(17), 8319–8326.PubMed

74.

Raimondi, C., Gradilone, A., Naso, G., Vincenzi, B., Petracca, A., Nicolazzo, C., Palazzo, A., Saltarelli, R., Spremberg, F., Cortesi, E., & Gazzaniga, P. (2011). Epithelial–mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Research & Treatment, 130(2), 449–455.

75.

Gunasinghe, N. P. A. D., Welss, A., Thompson, E. W., & Hugo, H. J. (2012). Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer & Metastasis Reviews. doi:10.1007/s10555-012-9377-5.

76.

Grabinski, N., Bartkowiak, K., Grupp, K., Brandt, B., Pantel, K., & Jücker, M. (2011). Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cellular Signalling, 23(12), 1952–1960.PubMed

77.

Matrone, M. A., Whipple, R. A., Balzer, E. M., & Martin, S. S. (2010). Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells. Cancer Research, 70(20), 7737–7741.PubMed

78.

Yokoyama, K., Kamata, N., Fujimoto, R., Tsutsumi, S., Tomonari, M., Taki, M., Hosokawa, H., & Nagayama, M. (2003). Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. International Journal of Oncology, 22(4), 891–898.PubMed

79.

Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., Campbell, L. L., Polyak, K., Brisken, C., Yang, J., & Weinberg, R. A. (2008). The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715.PubMed

80.

May, C. D., Sphyris, N., Evans, K. W., Werden, S. J., Guo, W., & Mani, S. A. (2011). Epithelial–mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Research, 13(1), 202.PubMed

81.

Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., & Sarkar, F. H. (2010). Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. Public Library of Science One, 5(8), e12445.PubMed

82.

Giannoni, E., Bianchini, F., Calorini, L., & Chiarugi, P. (2011). Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxidants and Redox Signaling, 14(12), 2361–2371.PubMed

83.

Toh, B., Wang, X., Keeble, J., Sim, W. J., Khoo, K., Wong, W. C., Kato, M., Prevost-Blondel, A., Thiery, J. P., & Abastado, J. P. (2011). Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. Public Library of Science Biology, 9(9), e1001162.

84.

Cooke, V. G., Lebleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., Sugimoto, H., Rocha, R. M., Damascena, A., Brentani, R. R., & Kalluri, R. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by Met signaling pathway. Cancer Cell, 21(1), 66–81.PubMed

85.

Wells, A., Yates, C., & Shepard, C. R. (2008). E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clinical and Experimental Metastasis, 25(6), 621–628.PubMed

86.

Chao, Y., Wu, Q., Acquafondata, M., Dhir, R., & Wells, A. (2011). Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Epub ahead of print: Cancer Microenvironment.

87.

Hazan, R. B., Qiao, R., Keren, R., Badano, I., & Suyama, K. (2004). Cadherin switch in tumor progression. Annals of the New York Academy of Sciences, 1014(1), 155–163.PubMed

88.

Satelli, A., & Li, S. (2011). Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Sciences, 68(18), 3033–3046.PubMed

89.

Bastid, J. (2012). EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Epub ahead of print: Cancer and Metastasis Review.

90.

Friedl, P., & Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 147(5), 992–1009.PubMed

91.

Nieto, M. A. (2011). The ins and outs of the epithelial to mesenchymal transition in health and disease. Annual Review of Cell and Developmental Biology, 27, 347–376.PubMed

92.

Alpaugh, M. L., Tomlinson, J. S., Kasraeian, S., & Barsky, S. H. (2002). Cooperative role of E-cadherin and sialyl-Lewis X/A-de ® cient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene, 21(22), 3631–3643.PubMed

93.

Bonnomet, A., Syne, L., Brysse, A., Feyereisen, E., Thompson, E. W., Noël, A., Foidart, J.-M., et al. (2011). A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. doi:10.1038/onc.2011.540.

94.

Howard, E. W., Leung, S. C., Yuen, H. F., Chua, C. W., Lee, D. T., Chan, K. W., Wang, X., & Wong, Y. C. (2008). Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clinical and Experimental Metastasis, 25(5), 497–508.PubMed

95.

Loric, S., Paradis, V., Gala, J. L., Berteau, P., Bedossa, P., Benoit, G., & Eschwège, P. (2001). Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. European Journal of Cancer, 37(12), 1475–1481.PubMed

96.

Saad, A. A., Awed, N. M., Abd Elkerim, N. N., El-Shennawy, D., Alfons, M. A., Elserafy, M. E., Darwish, Y. W., et al. (2010). Prognostic Significance of E-cadherin Expression and Peripheral Blood Micrometastasis in Gastric Carcinoma Patients. Annals of Surgical Oncology, 17(1), 3059–3067.PubMed

97.

Setoyama, T., Natsugoe, S., Okumura, H., Matsumoto, M., Uchikado, Y., & Aikou, T. (2007). Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer. British Journal of Surgery, 94(8), 984–991.PubMed

98.

Armstrong, A. J., Marengo, M. S., Oltean, S., Kemeny, G., Bitting, R., Turnbull, J., Herold, C. I., et al. (2011). Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research, 9(8), 997–1007.PubMed

99.

Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590.PubMed

100.

Padua, D., Zhang, X. H., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008). TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell, 133(1), 66–77.PubMed

101.

Giampieri, S., Manning, C., Hooper, S., Jones, L., Hill, C. S., & Sahai, E. (2009). Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nature Cell Biology, 11(11), 1287–1296.PubMed

102.

Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., Beitsch, P. D., Leitch, M., Hoover, S., Euhus, D., Haley, B., Morrison, L., Fleming, T. P., Herlyn, D., Terstappen, L. W., Fehm, T., Tucker, T. F., Lane, N., Wang, J., & Uhr, J. W. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152–8162.PubMed

103.

Yates, C. C., Shepard, C. R., Stolz, D. B., & Wells, A. (2007). Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. British Journal of Cancer, 96(8), 1246–1252.PubMed

104.

Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012). Targeting MET in cancer: rationale and progress. Nature Reviews Cancer, 12, 89–103.PubMed

105.

Aokage, K., Ishii, G., Ohtaki, Y., Yamaguchi, Y., Hishida, T., Yoshida, J., Nishimura, M., Nagai, K., & Ochiai, A. (2011). Dynamic molecular changes associated with epithelial–mesenchymal transition and subsequent mesenchymal–epithelial transition in the early phase of metastatic tumor formation. International Journal of Cancer, 128(7), 1585–1595.

106.

Putz, E., Witter, K., Offner, S., Models, W., Stosiek, P., Zippelius, A., Johnson, J., et al. (1999). Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Research, 59(1), 241–248.PubMed

107.

Willipinski-Stapelfeldt, B., Riethdorf, S., Assmann, V., Woelfle, U., Rau, T., Sauter, G., Heukeshoven, J., & Pantel, K. (2005). Changes in cytoskeletal protein composition indicative of an epithelial–mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clinical Cancer Research, 11(22), 8006–8014.PubMed

108.

Bartkowiak, K., Wieczorek, M., Buck, F., Harder, S., Moldenhauer, J., Effenberger, K. E., Pantel, K., Pater-Katalanic, J., & Brandt, B. H. (2009). Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. Journal of Proteome Research, 9(6), 3158–3168.

109.

Dachs, G. U., & Tozer, G. M. (2000). Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. European Journal of Cancer, 36, 1649–1660.PubMed

110.

Jiang, J., Tang, Y. L., & Liang, X. H. (2011). EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther., 11(8), 714–723.PubMed

111.

Kallergi, G., Markomanolaki, H., Giannoukaraki, V., Papadaki, M. A., Strati, A., Lianidou, E. S., Georgoulias, V., Mavroudis, D., & Agelaki, S. (2009). Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Research, 11(6), R84.PubMed

112.

Ameri, K., Luong, R., Zhang, H., Powell, A. A., Montgomery, K. D., Espinosa, I., Bouley, D. M., Harris, A. L., & Jeffrey, S. S. (2010). Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. British Journal of Cancer, 102(3), 561–569.PubMed

113.

Bartkowiak, K., Riethdorf, S., & Pantel, K. (2011). The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis. Cancer Microenvironment, 5, 59–72.PubMed

114.

Valdés, F., Alvarez, A. M., Locascio, A., Vega, S., Herrera, B., Fernández, M., Benito, M., Nieto, M. A., & Fabregat, I. (2002). The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Molecular Cancer Research, 1(1), 68–78.PubMed

115.

Barrallo-Gimeno, A., & Nieto, M. A. (2005). The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development, 132(14), 3151–3161.PubMed

116.

Peinado, H., Olmeda, D., & Cano, A. (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nature Reviews Cancer, 7(6), 415–428.PubMed

117.

Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009). Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells, 27(9), 2059–2068.PubMed

118.

Chen, X., Lingala, S., Khoobyari, S., Nolta, J., Zern, M. A., & Wu, J. (2011). Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. Journal of Hepatology, 55(4), 838–845.PubMed

119.

Theys, J., Jutten, B., Habets, R., Paesmans, K., Groot, A. J., Lambin, P., Wouters, B. G., Lammering, G., & Vooijs, M. (2011). E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiotherapy and Oncology, 99(3), 392–397.PubMed

120.

Bartkowiak, K., Effenberger, K. E., Harder, S., Andreas, A., Buck, F., Peter-Katalinic, J., Pantel, K., & Brandt, B. H. (2010). Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. Journal of Proteome Research, 9(6), 3158–3168.PubMed

121.

Prunotto, M., Compagnone, A., Bruschi, M., Candiano, G., Colombatto, S., Bandino, A., Petretto, A., Moll, S., Bochaton-Piallat, M. L., Gabbiani, G., Dimuccio, V., Parola, M., Citti, L., & Ghiggeri, G. (2010). Endocellular polyamine availability modulates epithelial-to-mesenchymal transition and unfolded protein response in MDCK cells. Lab Investigation, 90(6), 929–939.

122.

Zhong, Q., Zhou, B., Ann, D. K., Minoo, P., Liu, Y., Banfalvi, A., Krishnaveni, M. S., Dubourd, M., Demaio, L., Willis, B. C., Kim, K. J., duBois, R. M., Crandall, E. D., Beers, M. F., & Borok, Z. (2011). Role of endoplasmic reticulum stress in epithelial–mesenchymal transition of alveolar epithelial cells: effects of misfolded surfactant protein. American Journal of Respiratory Cell and Molecular Biology, 45(3), 498–509.PubMed

123.

Wouters, B. G., & Koritzinsky, M. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Reviews Cancer, 8, 851–864.PubMed

124.

Voss, M. J., Möller, M. F., Powe, D. G., Niggemann, B., Zänker, K. S., & Entschladen, F. (2011). Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer, 11, 158.PubMed

125.

Fernando, R. I., Castillo, M. D., Litzinger, M., Hamilton, D. H., & Palena, C. (2011). IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Research, 71(15), 5296–5306.PubMed

126.

Scheel, C., Eaton, E. N., Li, S. H., Chaffer, C. L., Reinhardt, F., Kah, K. J., Bell, G., Guo, W., Rubin, J., Richardson, A. L., & Weinberg, R. A. (2011). Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell, 145(6), 926–940.PubMed

127.

Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S., Gotwals, P. J., Koteliansky, V., & Arteaga, C. L. (2002). Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. Journal of Clinical Investigation, 109(12), 1551–1559.PubMed

128.

Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009). Stem cell and epithelial–mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research, 11(4), R46.PubMed

129.

Gradilone, A., Raimondi, C., Nicolazzo, C., Petracca, A., Gandini, O., Vincenzi, B., Naso, G., Aglianò, A. M., Cortesi, E., & Gazzaniga, P. (2011). Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. Journal of Cellular and Molecular Medicine, 15(5), 1066–1070.PubMed

130.

Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2011). Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 13(3), R59.PubMed

131.

Markou, A., Strati, A., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2011). Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clinical Chemistry, 57(3), 421–430.PubMed

132.

Mego, M., Mani, S. A., Lee, B. N., Li, C., Evans, K. W., Cohen, E. N., Gao, H., Jackson, S. A., Giordano, A., Hortobagyi, G. N., Cristofanilli, M., Lucci, A., & Reuben, J. M. (2012). Expression of epithelial–mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. International Journal of Cancer, 130(4), 808–816.

133.

Strati, A., Markou, A., Parisi, C., Politaki, E., Mavroudis, D., Georgoulias, V., & Lianidou, E. (2011). Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer, 11(1), 422.PubMed

134.

Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., & Fehm, T. (2012). Expression of stem cell and epithelial–mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Research, 14(1), R15.PubMed

135.

Hofman, V., Ilie, M. I., Long, E., Selva, E., Bonnetaud, C., Molina, T., Vénissac, N., Mouroux, J., Vielh, P., & Hofman, P. (2011). Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search Assay™ and the isolation by size of epithelial tumor cell method. International Journal of Cancer, 129(7), 1651–1660.

136.

Lecharpentier, A., Vielh, P., Perez-Moreno, P., Planchard, D., Soria, J. C., & Farace, F. (2011). Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer, 105(9), 1338–1341.PubMed

137.

Devriese, L. A., Bosma, A. J., van de Heuvel, M. M., Heemsbergen, W., Voest, E. E., & Schellens, J. H. (2012). Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. Lung Cancer, 75(2), 242–247.PubMed

138.

Wang, N., Shi, L., Li, H., Hu, Y., Du, W., Liu, W., Zheng, J., Huang, S., & Qu, X. (2012). Detection of circulating tumor cells and tumor stem cells in patients with breast cancer by using flow cytometry: a valuable tool for diagnosis and prognosis evaluation. Tumour Biology, 33, 561–569.PubMed

139.

Gazzaniga, P., Gradilone, A., Petracca, A., Nicolazzo, C., Raimondi, C., Iacovelli, R., Naso, G., et al. (2010). Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. Journal of Cellular and Molecular Medicine, 14(8), 2073–2077.PubMed

140.

Gradilone, A., Iacovelli, R., Cortesi, E., Raimondi, C., Gianni, W., Nicolazzo, C., Petracca, A., Palazzo, A., Longo, F., Frati, L., & Gazzaniga, P. (2011). Circulating tumor cells and “suspicious objects” evaluated through Cell Search® in metastatic renal cell carcinoma. Anticancer Research, 31(12), 4219–4221.PubMed

141.

Mor-Vaknin, N., Punturieri, A., Sitwala, K., & Markovitz, D. M. (2003). Vimentin is secreted by activated macrophages. Nature Cell Biology, 5(1), 59–63.PubMed

142.

Ishii, G., Ito, T.-K., Aoyagi, K., Fujimoto, H., Chiba, H., Hasebe, T., Fujii, S., et al. (2007). Presence of human circulating progenitor cells for cancer stromal fibroblasts in the blood of lung cancer patients. Stem Cells, 25(6), 1469–1477.PubMed

143.

Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994). Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Molecular Medicine, 1(1), 71–81.PubMed

144.

Barth, P. J., & Westhoff, C. C. (2007). CD34+ fibrocytes: morphology, histogenesis and function. Current Stem Cell Research and Therapy, 2(3), 221–227.PubMed

145.

Kitamura, N., Nishinarita, S., Takizawa, T., Tomita, Y., & Horie, T. (2000). Cultured human monocytes secrete fibronectin in response to activation by proinflammatory cytokines. Clinical and Experimental Immunology, 120(1), 66–70.PubMed

146.

Campbell, I., Qiu, W., & Haviv, I. (2011). Genetic changes in tumour microenvironments. Journal of Pathology, 223(4), 450–458.PubMed

Title: Plasticity of disseminating cancer cells in patients with epithelial malignancies
Authors: Natalia Bednarz-Knoll
Catherine Alix-Panabières
Klaus Pantel
Publication date: 01-12-2012
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9370-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2012

Biographies

Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?

Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes

Mouse models of breast cancer metastasis to bone

Transcription factor PROX1: its role in development and cancer

Role of the EpCAM (CD326) in prostate cancer metastasis and progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer